포스터 다운로드_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

KR

사회적 책임

합작연구개발

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

동물/세포 모델

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

유전자 편집

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

자료 다운로드

포스터 다운로드

홍보센터

뉴스 및 각종 자료 열람

논문게재실적

자료 다운로드

포스터 다운로드

제품정보 다운로드

AACR 2025: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)

AACR 2025: BCG033: a first-in-class PTK7×TROP2 bispecific ADC demonstrating potent and broad efficacy in various preclinical models

AACR 2025: A novel PD-1, IL12Rβ1 and IL12Rβ2 humanized mouse model for evaluating the combined efficacy of anti-tumor therapies

AACR 2025: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical toxicity evaluation of human IL-12 analogs

AACR 2025: YH006: a next-generation CTLA-4×OX40 Treg antagonist, demonstrates superior tumor-infiltrating Treg-depletion efficacy and favorable manufacturability

AACR 2025: Humanized GDF15 model for simulating weight loss induced by GDF15 secretion in tumors

AACR 2025: Animal models for evaluating the efficacy of anti-human HER2 ADC alone or in combination with IO therapy

AACR 2025: Development of TNFR2, TNFR1 and LTBR humanized mouse model for evaluating anti-human LTBR antibodies

AACR 2025: Preclinical evaluation of CD3/DLL3 bispecific antibody in syngeneic and humanized mouse models for solid tumor treatment

1 2 3 4 5 … 14